Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by whisky11 on Apr 14, 2021 3:45pm

L2

Apr 14, 2021 03:40:00 PM EDT
 
CLASCLARITAS PHARMACCA
$ 0.075
0.025
(50.00%)
Bid (Size)
0.07 (111)
Ask (Size)
0.075 (701)
Volume
3,594,152
Hide Level II Quotes

.
Level II Quotes
Orders
Shares
Bid
Ask
Shares
Orders
7
95,000
0.07
0.075
694,000
9
11
575,000
0.065
0.08
82,000
7
13
643,000
0.06
0.085
407,000
6
12
438,000
0.055
0.09
161,000
5
14
980,000
0.05
0.095
429,000
6
Comment by mavericks2020 on Apr 14, 2021 3:48pm
AFTER 0.075 WE HAVE THIN ASK
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities